- Home
- EPSM vs TIL Comparison
EPSM vs TIL Comparison
Compare EPSM & TIL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EPSM
- TIL
- Stock Information
- Founded
- EPSM 2010
- TIL 2018
- Country
- EPSM China
- TIL United States
- Employees
- EPSM N/A
- TIL N/A
- Industry
- EPSM
- TIL Biotechnology: Pharmaceutical Preparations
- Sector
- EPSM
- TIL Health Care
- Exchange
- EPSM Nasdaq
- TIL Nasdaq
- Market Cap
- EPSM 178.3M
- TIL 177.1M
- IPO Year
- EPSM 2025
- TIL 2021
- Fundamental
- Price
- EPSM $3.92
- TIL $12.28
- Analyst Decision
- EPSM
- TIL Strong Buy
- Analyst Count
- EPSM 0
- TIL 5
- Target Price
- EPSM N/A
- TIL $100.67
- AVG Volume (30 Days)
- EPSM 3.7M
- TIL 72.4K
- Earning Date
- EPSM 12-16-2025
- TIL 11-13-2025
- Dividend Yield
- EPSM N/A
- TIL N/A
- EPS Growth
- EPSM N/A
- TIL N/A
- EPS
- EPSM 0.02
- TIL N/A
- Revenue
- EPSM $12,518,070.00
- TIL N/A
- Revenue This Year
- EPSM N/A
- TIL N/A
- Revenue Next Year
- EPSM N/A
- TIL N/A
- P/E Ratio
- EPSM $165.92
- TIL N/A
- Revenue Growth
- EPSM N/A
- TIL N/A
- 52 Week Low
- EPSM $1.31
- TIL $10.80
- 52 Week High
- EPSM $155.00
- TIL $42.79
- Technical
- Relative Strength Index (RSI)
- EPSM N/A
- TIL 35.84
- Support Level
- EPSM N/A
- TIL $13.53
- Resistance Level
- EPSM N/A
- TIL $13.50
- Average True Range (ATR)
- EPSM 0.00
- TIL 1.36
- MACD
- EPSM 0.00
- TIL -0.09
- Stochastic Oscillator
- EPSM 0.00
- TIL 16.46
About EPSM Epsium Enterprise Limited Ordinary Shares
Epsium Enterprise Ltd is a holding company and conducts business through its subsidiaries. It is engaged in import trading and wholesale selling of beverages in Macau. The company imports and sells a range of beverages, alcoholic beverages, and a small quantity of tea and fruit juice. The alcoholic beverages it sells include Chinese liquor, French cognac, Scottish whiskey, fine wine, Champagne, and other miscellaneous beverage alcohol.
About TIL Instil Bio Inc.
Instil Bio Inc is a clinical-stage biopharmaceutical company focused on developing a cell therapy pipeline of autologous tumor infiltrating lymphocyte, or TIL, therapies for the treatment of patients with cancer. It is also engaged in developing a novel class of genetically engineered TIL therapies using its Co-Stimulatory Antigen Receptor, or CoStAR, platform. Its pipeline includes ITIL-306 which expresses a CoStAR molecule designed to recognize, a tumor-associated antigen that is expressed on numerous solid tumors, including ovarian cancer, uterine cancer, NSCLC, and renal cancer.